{
  "id": "5896d3e278275d0c4a000012",
  "type": "yesno",
  "question": "Is siltuximab effective for Castleman disease?",
  "ideal_answer": "Yes, siltuximab , a chimeric human-mouse monoclonal antibody to IL6, is approved for the treatment of patients with multicentric Castleman disease who are human immunodeficiency virus negative and human herpesvirus-8 negative.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25310208",
    "http://www.ncbi.nlm.nih.gov/pubmed/26124203",
    "http://www.ncbi.nlm.nih.gov/pubmed/26749192",
    "http://www.ncbi.nlm.nih.gov/pubmed/25601959",
    "http://www.ncbi.nlm.nih.gov/pubmed/26634298",
    "http://www.ncbi.nlm.nih.gov/pubmed/25110138",
    "http://www.ncbi.nlm.nih.gov/pubmed/25042199",
    "http://www.ncbi.nlm.nih.gov/pubmed/23659971",
    "http://www.ncbi.nlm.nih.gov/pubmed/26327301",
    "http://www.ncbi.nlm.nih.gov/pubmed/25784388",
    "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
    "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
    "http://www.ncbi.nlm.nih.gov/pubmed/27152394",
    "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
    "http://www.ncbi.nlm.nih.gov/pubmed/26394632",
    "http://www.ncbi.nlm.nih.gov/pubmed/26869762",
    "http://www.ncbi.nlm.nih.gov/pubmed/25736164",
    "http://www.ncbi.nlm.nih.gov/pubmed/25884809"
  ],
  "snippets": [
    {
      "text": "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The recent approvals in North America, Europe and Brazil of siltuximab, a monoclonal antibody against IL-6, for iMCD now provide a safe and effective therapy that targets a key aspect of pathogenesis. In the first ever randomized, placebo-controlled trial in iMCD, siltuximab significantly reduced disease burden and symptoms in a large portion (34%) of patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite recent significant advances in our understanding of this disease and the increasing therapeutic experience with rituximab, tocilizumab and siltuximab, there are still difficult questions concerning its aetiology, prognosis and optimal treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26749192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging treatments in Castleman disease - a critical appraisal of siltuximab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab for multicentric Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110138",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26394632",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327301",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152394",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab: a new option for the management of Castleman's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: To evaluate the safety and pharmacokinetics of siltuximab, an anti-interleukin-6 chimeric monoclonal antibody (mAb) in patients with B-cell non-Hodgkin lymphoma (NHL), multiple myeloma, or Castleman disease.EXPERIMENTAL DESIGN: In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dose selection of siltuximab for multicentric Castleman's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784388",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, modeling and simulation of the pharmacokinetic (PK)/pharmacodynamic (PD) relationship between siltuximab and CRP were used to support dose selection for multicentric Castleman's disease (CD).METHODS: PK/PD modeling was applied to explore the relationship between siltuximab PK and CRP suppression following intravenous siltuximab infusion in 47 patients with B cell non-Hodgkin's lymphoma (n\u00a0=\u00a017), multiple myeloma (n\u00a0=\u00a013), or CD (n\u00a0=\u00a017).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784388",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Three (6%) of 53 patients had serious adverse events judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction, sepsis).Siltuximab plus best supportive care was superior to best supportive care alone for patients with symptomatic multicentric Castlemans disease and well tolerated with prolonged exposure",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled study of MCD.This preplanned safety analysis was conducted to evaluate the long-term safety of siltuximab treatment among 19 patients with MCD who had stable disease or better and were enrolled in a phase-1 study and subsequent ongoing, open-label, phase-2 extension study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26327301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124203",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab for multicentric Castleman disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110138",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "EXPERIMENTAL DESIGN: In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there are more effective therapeutic alternatives in multicentric Castleman disease: treatment with monotherapy of rituximab or in combination therapy with immunomodulatory drugs (thalidomide or lenalidomide, treatment with anti-IL-6 (siltuximab) or against its receptor (tocilizumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25873122",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate the safety and pharmacokinetics of siltuximab, an anti-interleukin-6 chimeric monoclonal antibody (mAb) in patients with B-cell non-Hodgkin lymphoma (NHL), multiple myeloma, or Castleman disease.In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25601959",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical benefit response (CBR; composite of hemoglobin, fatigue, anorexia, fever/night sweats, weight, largest lymph node size) was also evaluated in Castleman disease.Sixty-seven patients received a median of 16 siltuximab doses for a median of 8.5 (maximum 60.5) months; 29 were treated 1 year or longer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23659971",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent approvals in North America, Europe and Brazil of siltuximab, a monoclonal antibody against IL-6, for iMCD now provide a safe and effective therapy that targets a key aspect of pathogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No dose-limiting toxicity was reported, and only three patients had grade 3 or higher adverse events after a median exposure of 331 days (range, 1 to 1,148 days).These interim results strongly suggest that siltuximab is an effective treatment with favorable safety for the management of CD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD.METHODS: We report interim results from an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multicentric or unresectable, unicentric CD received siltuximab at 1-, 2-, or 3-week intervals.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Siltuximab for multicentric Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110138",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634298",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Emerging treatments in Castleman disease - a critical appraisal of siltuximab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26869762",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27152394",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab: a new option for the management of Castleman's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685858",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25042199",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26394632",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}